Is Fibromyalgia An Endocrine/Endorphin Deficit Disorder? Is Low Dose Naltrexone a New Treatment Option?
Authors:
- Seethalakshmi RamanathanSRSeethalakshmi Ramanathan
- Jaak PankseppJPJaak Panksepp
- Brian JohnsonBJBrian Johnson
- 1 November 2012
- journal article
- case report
- Published by Elsevier in Psychosomatics
- Vol. 53 (6) , 591-594
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Fibromyalgia Syndrome: A Discussion of the Syndrome and PharmacotherapyAmerican Journal of Therapeutics, 2010
- Mechanisms of Opioid-Mediated Inhibition of Human T Cell Receptor SignalingThe Journal of Immunology, 2009
- Fibromyalgia Symptoms Are Reduced by Low-Dose Naltrexone: A Pilot StudyPain Medicine, 2009
- Effects of Naltrexone on Pain Sensitivity and Mood in Fibromyalgia: No Evidence for Endogenous Opioid PathophysiologyPLOS ONE, 2009
- Low-dose naltrexone for disease prevention and quality of lifeMedical Hypotheses, 2009
- Neuroendocrine Abnormalities in Fibromyalgia and Related DisordersThe American Journal of the Medical Sciences, 1998
- Fibromyalgia Is Not a Muscle DisorderThe American Journal of the Medical Sciences, 1998
- No evidence for endorphin deficiency in fibromyalgia following investigation of cerebrospinal fluid (CSF) dynorphin A and Met-enkephalin-Arg6-Phe7Pain, 1991
- The american college of rheumatology 1990 criteria for the classification of fibromyalgiaArthritis & Rheumatism, 1990
- Normative Model for Cold Pressor TestAmerican Journal of Physical Medicine & Rehabilitation, 1989